| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1038/S41575-020-0293-9 |
| P698 | PubMed publication ID | 32303700 |
| P50 | author | Laurent Peyrin-Biroulet | Q30248039 |
| Peter Bossuyt | Q57155093 | ||
| Simon Travis | Q87729521 | ||
| Silvio Danese | Q89573798 | ||
| P2093 | author name string | Lieven Pouillon | |
| P2860 | cites work | Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor | Q27024505 |
| The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration | Q27860581 | ||
| Review of head-to-head study designs in rheumatoid arthritis | Q28073708 | ||
| Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study | Q31085610 | ||
| Methods in comparative effectiveness research | Q36417734 | ||
| Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study | Q36610390 | ||
| Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial | Q37196938 | ||
| Blinding in pharmacological trials: the devil is in the details | Q37323277 | ||
| Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study | Q37616966 | ||
| Industry sponsorship and selection of comparators in randomized clinical trials | Q37668679 | ||
| Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease | Q38045701 | ||
| Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. | Q38211991 | ||
| Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. | Q38572827 | ||
| IOIBD technical review on endoscopic indices for Crohn's disease clinical trials | Q38583688 | ||
| Meta-analysis using individual participant data from randomised trials: opportunities and limitations created by access to raw data | Q38619218 | ||
| American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. | Q38642750 | ||
| Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial | Q38787053 | ||
| Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases | Q38943959 | ||
| The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses | Q38952676 | ||
| Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial | Q38966960 | ||
| Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. | Q39098635 | ||
| Network meta-analysis: an introduction for clinicians | Q39134420 | ||
| 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial | Q39977343 | ||
| Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial | Q40071528 | ||
| Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). | Q40583199 | ||
| Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up | Q40926333 | ||
| Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. | Q41582729 | ||
| An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies | Q41962966 | ||
| Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis | Q42172189 | ||
| Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease | Q43531369 | ||
| Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial | Q46150166 | ||
| Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-based vs Trough Concentration-based Dosing of Infliximab | Q46210756 | ||
| Population Health Management for Inflammatory Bowel Disease | Q46265941 | ||
| Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis | Q46452033 | ||
| Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, or Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. | Q47216133 | ||
| Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey | Q47724175 | ||
| Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial | Q49167560 | ||
| Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. | Q50953891 | ||
| Meta-analysis and the science of research synthesis. | Q51148876 | ||
| Blinding in randomised trials: hiding who got what. | Q52937785 | ||
| Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review for Development of a Core Outcome Set. | Q53076589 | ||
| Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. | Q53122367 | ||
| Cortisone in ulcerative colitis; final report on a therapeutic trial. | Q55499879 | ||
| Infliximab, azathioprine, or combination therapy for Crohn's disease | Q56988763 | ||
| Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials | Q57210849 | ||
| Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician | Q57789414 | ||
| Superiority and non-inferiority: two sides of the same coin? | Q58732954 | ||
| Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn’s Disease | Q62475972 | ||
| Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis | Q64137296 | ||
| Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease | Q64261195 | ||
| New biologics and small molecules in inflammatory bowel disease: an update. | Q64917770 | ||
| Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis | Q79596195 | ||
| Once-daily, high-concentration MMX mesalamine in active ulcerative colitis | Q79621238 | ||
| Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population | Q83463037 | ||
| Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis | Q87263251 | ||
| Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations | Q88041740 | ||
| Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data | Q88398467 | ||
| Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis | Q88478503 | ||
| Head-to-head trials of systemic psoriasis therapies: a systematic review of study design and maximum acceptable treatment differences | Q89495844 | ||
| Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis | Q90281122 | ||
| Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness | Q90932494 | ||
| Big data in IBD: a look into the future | Q91117785 | ||
| Interrogating host immunity to predict treatment response in inflammatory bowel disease | Q91452268 | ||
| Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes | Q91729542 | ||
| Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure | Q91755844 | ||
| Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review | Q92193830 | ||
| Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development | Q92228977 | ||
| Most noninferiority trials were not designed to preserve active comparator treatment effects | Q92281117 | ||
| Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials | Q92818920 | ||
| Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases | Q92953362 | ||
| Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis | Q93012972 | ||
| Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals | Q93340410 | ||
| P2507 | corrigendum / erratum | Author Correction: Head-to-head trials in inflammatory bowel disease: past, present and future | Q104750134 |
| P921 | main subject | inflammatory bowel diseases | Q917447 |
| P577 | publication date | 2020-04-17 | |
| P1433 | published in | Nature Reviews Gastroenterology & Hepatology | Q2108255 |
| P1476 | title | Head-to-head trials in inflammatory bowel disease: past, present and future |
Search more.